

# Cardiometabolic disease and features of depression and bipolar disorder: population-based, cross-sectional study

Daniel J. Martin, Zia Ul-Haq, Barbara I. Nicholl, Breda Cullen, Jonathan Evans, Jason M. R. Gill, Beverly Roberts, John Gallacher, Daniel Mackay, Andrew McIntosh, Matthew Hotopf, Nick Craddock, Ian J. Deary, Jill P. Pell and Daniel J. Smith

## Background

The relative contribution of demographic, lifestyle and medication factors to the association between affective disorders and cardiometabolic diseases is poorly understood.

## Aims

To assess the relationship between cardiometabolic disease and features of depression and bipolar disorder within a large population sample.

## Method

Cross-sectional study of 145 991 UK Biobank participants: multivariate analyses of associations between features of depression or bipolar disorder and five cardiometabolic outcomes, adjusting for confounding factors.

## Results

There were significant associations between mood disorder features and 'any cardiovascular disease' (depression odds ratio (OR)=1.15, 95% CI 1.12–1.19; bipolar OR=1.28, 95% CI 1.14–1.43) and with hypertension (depression OR=1.15, 95% CI 1.13–1.18; bipolar OR=1.26, 95% CI 1.12–1.42). Individuals

with features of mood disorder taking psychotropic medication were significantly more likely than controls not on psychotropics to report myocardial infarction (depression OR=1.47, 95% CI 1.24–1.73; bipolar OR=2.23, 95% CI 1.53–3.57) and stroke (depression OR=2.46, 95% CI 2.10–2.80; bipolar OR=2.31, 95% CI 1.39–3.85).

## Conclusions

Associations between features of depression or bipolar disorder and cardiovascular disease outcomes were statistically independent of demographic, lifestyle and medication confounders. Psychotropic medication may also be a risk factor for cardiometabolic disease in individuals without a clear history of mood disorder.

## Declaration of interest

None.

## Copyright and usage

© The Royal College of Psychiatrists 2016.

Bipolar disorder and major depression are common affective disorders, affecting approximately 2%<sup>1</sup> and 16%<sup>2</sup> of the population respectively. In addition to significant psychiatric morbidity, they also have an adverse impact on social and occupational functioning, quality of life and physical health,<sup>3–8</sup> and often coexist with cardiovascular and metabolic diseases.<sup>9</sup> The association of both major depressive disorder and bipolar disorder with cardiometabolic risk factors, vascular disease and poor cardiovascular outcomes is well recognised.<sup>10–12</sup>

Although psychotropic medications alter cardiovascular risk profiles (through weight gain, hypertension, dyslipidaemia and glucose dysregulation), their use is also associated with a range of demographic and lifestyle factors, including social deprivation, smoking and alcohol use.<sup>13</sup> To date, there has been no large-scale population-based study in the UK that has assessed associations between a lifetime history of depressive or bipolar features and adverse cardiometabolic outcomes while also taking account of a wide range of potential confounding factors, including psychotropic medications.

Beyond the UK, there have been a number of large-scale reports assessing the association between mood disorders and cardiometabolic disease, including the National Comorbidity Study Replication<sup>2</sup> and the World Mental Health Survey.<sup>7</sup> Although very informative, these studies did not assess the wide range of covariates we have been able to include in our analyses. The landmark UK Biobank cohort,<sup>14</sup> comprising over half a million adults in middle age, represents a unique opportunity to explore these associations at a population level (both cross-sectionally and prospectively) and has the potential to inform future mechanistic studies and the development of population-level interventions. Here

we assess relationships between five cardiometabolic diseases (myocardial infarction, angina, hypertension, diabetes and stroke) and lifetime features of affective disorders (major depression and bipolar disorder) within UK Biobank. In additional subanalyses we also assess the effect of psychotropic medication on cardiometabolic disease.

## Method

### Data source

UK Biobank is a large prospective cohort of more than 502 000 residents of the UK, aged between 40 and 70 years.<sup>15</sup> It is one of the largest resources worldwide for studying the genetic, environmental, medication and lifestyle factors that cause or prevent disease in middle and older age. Recruitment was undertaken over a 4-year period, from 2006 to 2010. In the final 2 years of UK Biobank recruitment, 172 751 participants were assessed in detail with respect to lifetime features of bipolar disorder and major depression. Eligibility for inclusion in our study was restricted to the 145 991 participants who provided complete data on lifetime features of mood disorder and complete data on self-reported cardiometabolic disease status.<sup>15</sup>

### Data collection and ethical approval

Participants attended one of 22 assessment centres located across Great Britain. They completed a touchscreen questionnaire that collected information on demographics (including age, gender, ethnicity and postcode), health-related behaviours (including smoking status and alcohol consumption) and a self-report of physician-diagnosed medical conditions, including diabetes, hypertension, myocardial infarction, angina and stroke. Current

medication was recorded with assistance from a member of trained clinic staff, who also used standard operating procedures to measure height and weight for body mass index (BMI) calculation. This study was conducted under generic approval from the NHS National Research Ethics Service (approval letter dated 17 June 2011, Ref 11/NW/0382) and full written informed consent was gained from participants at the point of data collection.

## Definitions

Criteria for a lifetime history of clinically significant features of bipolar disorder or depression were based on responses to questions within the baseline touchscreen questionnaire (see online supplements DS1 and DS2). Although not diagnostic of bipolar disorder or major depressive disorder, these questions were similar to questions assessing mood disorders within structured diagnostic assessment instruments. To some extent the validity of these questions has been supported internally within this data-set by comparisons of gender distribution, socioeconomic status, self-reported health rating, current depressive symptoms and smoking status.<sup>15</sup>

For the purposes of this study, participants were categorised into three groups: those with bipolar disorder features, those with features of major depression and a control group (Appendix).<sup>15,16</sup> 'Any cardiovascular disease' was defined as the self-report of a previous physician diagnosis of hypertension, myocardial infarction, angina and/or stroke. Diabetes was also defined by self-report. BMI was determined through anthropometric measurements carried out at the assessment centre and categorised into underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), class I obese (30.0–34.9 kg/m<sup>2</sup>), class II obese (35.0–39.9 kg/m<sup>2</sup>) and class III obese (≥40 kg/m<sup>2</sup>).<sup>17</sup> Smoking status, frequency of alcohol consumption and ethnic group were self-reported on the touchscreen questionnaire. Smoking status was classified as 'current smoker', 'previous smoker' or 'never smoked' and alcohol use was classified as 'daily/almost daily', '3–4 times per week', '1–2 times per week', '1–3 times/month', 'special occasions only' or 'never'. Ethnicity was categorised as: 'White', 'mixed', 'Asian/Asian British', 'Black/Black British', 'Chinese', and 'other'. The Townsend deprivation index – an area-based measure of socioeconomic status derived from information collected in the census on car ownership, overcrowding, owner-occupation and unemployment – includes both positive and negative values, with positive values indicating higher levels of deprivation.<sup>17</sup> Townsend scores were divided into quintiles (within the study population) to facilitate comparisons. The use of current medication (including psychotropics) was self-reported by participants and a comprehensive list of commonly used psychotropics was identified (online supplement DS3). Participants were classified as using psychotropic medication if they reported currently taking any of these medications.

## Statistical analyses

Differences in baseline characteristics between the three groups (control, depressive features and bipolar features) were analysed using the chi-squared test for categorical data and the chi-squared test for trend for ordinal data. We used separate logistic regression models to examine the associations between mood group and cardiometabolic disease categories ('any cardiovascular disease' (not including diabetes), diabetes, hypertension, myocardial infarction, angina or stroke), with controls as the referent group. These primary outcomes were used to provide a more comprehensive analysis of common cardiometabolic comorbidities in the depressive and bipolar features groups. Models were initially adjusted for age, gender, socioeconomic deprivation and ethnicity (a partially adjusted model) and then repeated including

additional covariates: smoking status, frequency of alcohol use, BMI and the use of psychotropic medication (fully adjusted model). Interaction tests for gender were undertaken and subgroup analyses carried out as appropriate.

To explore the relative contribution of psychotropic medication to cardiometabolic risk across the mood spectrum, we carried out a subanalysis to assess the effect of current psychotropic medication and mood group status on cardiometabolic disease across the mood spectrum. Six groups were created: individuals with no mood disorder features and not currently taking psychotropic medication (our referent group); individuals with no mood disorder features but currently taking one or more psychotropic medications; individuals with depressive features not currently taking psychotropic medication; individuals with depressive features currently taking one or more psychotropic medications; individuals with features of bipolar disorder not currently taking any psychotropic medication; and individuals with features of bipolar disorder currently taking psychotropic medication.

Differences in cardiometabolic outcomes between different mood and medication status groups were reported as prevalences and then analysed using the chi-squared test for categorical data. We again used separate logistic regression models to examine associations between medication and mood disorder group with cardiometabolic disease (diabetes, myocardial infarction, angina, hypertension or stroke). As noted above, controls who were not currently taking psychotropic medication were chosen as the most appropriate referent group. These models were adjusted for age, gender, socioeconomic deprivation and ethnicity, smoking, alcohol and BMI. All statistical analyses were performed using Stata version 12.1. Statistical significance was defined conservatively as  $P < 0.001$ .

## Results

### Group characteristics: bipolar features, depression features and controls

A total of 172 751 UK Biobank participants were assessed at baseline with respect to lifetime history of depressive and bipolar features. Of these, complete data on mood disorder features and cardiometabolic disease status were available for 145 991 (84.5%). From this sample, according to our criteria in the Appendix, 1557 (1.07%) had features of bipolar disorder, 30 990 (21.23%) had features of major depression and 113 444 (77.71%) had no significant features of mood disorder (controls) (Table 1).

Participants with features of depression were younger and more likely to be women (Table 1). Current smoking was most common in the bipolar features group (21.3%), followed by the depressive features group (12.7%) and then the non-mood-disordered control group (8.8%) (Table 2). The proportions of different levels of socioeconomic deprivation were mixed between the groups, but of note was that 34.6% of the bipolar features group were in the most deprived quintile, compared with 22.4% for the depressive features group, and 19.2% for the control group. White ethnicity was most common in the depressive features group and least common in the bipolar features group (Table 1).

Patterns of alcohol use were similar between groups (Table 2) and obesity was more common in both the depressive features and bipolar features groups compared with the control group (Table 1). Rates of current psychotropic medication use were highest in the groups with bipolar (32.1%) and depressive (20.6%) features and lowest within the control group (3.4%) (Table 2).

### Prevalence of cardiometabolic disease

The prevalence of 'any cardiovascular disease' was highest in the bipolar features group (34.5%), followed by the depressive

**Table 1** Sociodemographic characteristics (*n* = 145 991)

	<i>n</i> (%)			<i>P</i> <sup>a</sup>
	Control group	Depression features group	Bipolar features group	
Participants	113 444 (77.7)	30 990 (21.2)	1557 (1.1)	
Gender				
Female	57 082 (50.3)	20 004 (64.5)	766 (49.2)	<0.001
Male	56 362 (49.7)	10 986 (35.5)	791 (50.8)	
Age, years				
39–49	25 215 (22.2)	8027 (25.9)	492 (31.6)	<0.001
50–60	40 012 (35.3)	12 351 (39.9)	624 (40.1)	
61–72	48 217 (42.5)	10 612 (34.2)	441 (28.3)	
Body mass index category				
Underweight	552 (0.5)	159 (0.5)	15 (1.0)	<0.001
Normal weight	37 613 (33.2)	9783 (31.6)	451 (29.0)	
Overweight	48 835 (43.1)	12 578 (40.6)	614 (39.4)	
Class I obese	19 473 (17.2)	5708 (18.4)	328 (21.1)	
Class II obese	5186 (4.6)	1888 (6.1)	108 (6.9)	
Class III obese	1785 (1.6)	874 (2.8)	41 (2.6)	
Townsend score quintile				
1 (least deprived)	19 541 (17.1)	4802 (15.5)	169 (10.9)	<0.001
2	23 102 (20.4)	5781 (18.7)	205 (13.2)	
3	23 659 (20.9)	6270 (20.2)	260 (16.7)	
4	25 414 (22.4)	7197 (23.2)	384 (24.7)	
5 (most deprived)	21 728 (19.2)	6940 (22.4)	539 (34.6)	
Ethnicity				
White	103 786 (91.5)	29 295 (94.5)	1385 (89.0)	<0.001
Mixed	777 (0.7)	264 (0.9)	25 (1.6)	
Asian/Asian British	3811 (3.4)	564 (1.8)	65 (4.2)	
Black/Black British	3248 (2.9)	522 (1.7)	50 (3.2)	
Chinese	471 (0.4)	49 (0.2)	6 (0.4)	
Other	1351 (1.2)	296 (1.0)	26 (1.7)	

a. Chi-squared test.

features group (30.6%) and lowest in the control group (28.7%). Similar patterns were observed for hypertension, myocardial infarction, angina and stroke (Table 2). Cardiometabolic disease frequencies were also calculated for men and women. Men had consistently higher rates of all cardiometabolic diseases and, in general, rates of cardiometabolic disease were highest in the bipolar features group, followed by the depressive features group and the control group (Table 2).

### Partially adjusted model

On multivariate logistic regression (adjusting for age, gender, socioeconomic deprivation and ethnicity), odds ratios (ORs) for all cardiometabolic outcomes were significantly increased in the depressive features and the bipolar features groups relative to controls (all  $P < 0.001$ , Table 3, see also online Table DS1 for a more detailed version of this table that includes an analysis by gender). In general, the odds of each cardiometabolic outcome, as well as the odds of having ‘any cardiovascular illness’, increased across the two mood groups, in the depressive features group and the bipolar features group (Table 3). It should be noted, however, that findings for the bipolar features group with respect to diabetes and stroke were not statistically significant. The highest odds ratios in the partially adjusted model for the combined male and female group were for myocardial infarction (OR = 1.90, 95% CI 1.44–2.51) and angina (OR = 1.69, 95% CI 1.30–2.19) within the bipolar features group relative to controls, and for diabetes (OR = 1.29, 95% CI 1.22–1.37) in the depressive features group relative to controls (Table 3).

There was a significant interaction between mood disorder and gender in predicting risk of having ‘any cardiovascular illness’ ( $P < 0.001$ ) and subgroup analyses by gender were subsequently carried out (Table DS1). Men with bipolar features had elevated

odds ratios for myocardial infarction (2.02, 95% CI 1.50–2.72). The odds ratio for myocardial infarction in women was not significantly elevated in the partially adjusted group (1.37, 95% CI 0.65–2.92). Women with bipolar features had slightly higher odds ratios for any cardiovascular disease (1.55, 95% CI 1.32–1.83 in women *v.* 1.46, 95% CI 1.25–1.69 in men) and for hypertension (1.46, 95% CI 1.24–1.73 in women *v.* 1.42, 95% CI 1.22–1.66 in men) (Table DS1).

The odds ratios for specific conditions within the depressive features group were broadly similar for men and women. For angina this was OR = 1.54 (95% CI 1.40–1.69) for men and OR = 1.43 (95% CI 1.27–1.61) for women. Similarly, for diabetes the OR for men was 1.32 (95% CI 1.23–1.44) and for women the OR was 1.25 (95% CI 1.15–1.36). In women with depressive features, the odds ratio for stroke was 1.70 (95% CI 1.47–1.97) compared with 1.53 (95% CI 1.33–1.76) for men (Table DS1).

### Fully adjusted model

On additional adjustment for smoking status, frequency of alcohol consumption, BMI and the use of psychotropic medication, the risk of having ‘any cardiovascular illness’ remained significantly elevated in both the depressive (OR = 1.15, 95% CI 1.12–1.19) and the bipolar features groups (OR = 1.28, 95% CI 1.14–1.43) (Table 3). This pattern was also largely present in a subgroup analysis by gender (Table DS1). In the fully adjusted model, odds ratios for hypertension and myocardial infarction were also significantly elevated in the combined male and female groups (hypertension: depression features group OR = 1.15, 95% CI 1.13–1.18, bipolar features group OR = 1.26, 95% CI 1.12–1.42; myocardial infarction: depression features group OR = 1.18, 95% CI 1.08–1.30) (Table 3).

**Table 2** Lifestyle and clinical characteristics (*n* = 145 991)

	<i>n</i> (%)			<i>P</i> <sup>a</sup>
	Control group ( <i>n</i> = 113 444)	Depression features group ( <i>n</i> = 30 990)	Bipolar features group ( <i>n</i> = 1 557)	
Alcohol consumption				
Daily/almost daily	23 377 (21.0)	6 134 (19.8)	318 (20.4)	<0.001
3–4 times/week	26 571 (23.4)	6 588 (21.2)	263 (16.9)	
1–2 times/week	29 107 (25.7)	7 467 (24.1)	337 (21.6)	
1–3 times/month	12 317 (10.9)	3 943 (12.7)	196 (12.6)	
Special occasions only	12 737 (11.2)	4 091 (13.2)	231 (14.8)	
Never	8 935 (7.9)	2 767 (8.9)	212 (13.6)	
Smoking status				
Never	65 154 (57.4)	15 647 (50.5)	667 (42.8)	<0.001
Previous	38 320 (33.8)	11 412 (36.8)	559 (35.9)	
Current	9 970 (8.8)	3 931 (12.7)	331 (21.3)	
Psychotropic medication				
No	109 577 (96.6)	24 603 (79.4)	1 057 (67.9)	<0.001
Yes	3 867 (3.4)	6 387 (20.6)	500 (32.1)	
Cardiovascular disease any				
No	80 854 (71.3)	21 516 (69.4)	1 020 (65.5)	<0.001
Yes	32 590 (28.7)	9 474 (30.6)	537 (34.5)	
Diabetes				
No	107 457 (94.7)	29 260 (94.4)	1 449 (93.1)	0.002
Yes	5 987 (5.3)	1 730 (5.6)	108 (6.9)	
Hypertension				
No	83 762 (73.8)	22 316 (72.0)	1 073 (68.9)	<0.001
Yes	29 682 (26.2)	8 674 (28.0)	484 (31.1)	
Myocardial infarction				
No	111 046 (97.9)	30 314 (97.8)	1 502 (96.5)	0.001
Yes	2 398 (2.1)	676 (2.2)	55 (3.5)	
Angina				
No	110 296 (97.2)	29 979 (96.7)	1 494 (96.0)	<0.001
Yes	3 148 (2.8)	1 011 (3.3)	63 (4.0)	
Stroke				
No	111 974 (98.7)	30 428 (98.2)	1 523 (97.8)	<0.001
Yes	1 470 (1.3)	562 (1.8)	34 (2.2)	

a. Chi-squared tests.

Differences in odds ratios for angina and stroke within the fully adjusted, combined group analyses were not statistically significant. There were, however, elevations in odds of cardiovascular conditions within the depressive features group, most notably for stroke (OR = 1.26, 95% CI 1.13–1.40) (Table 3). Associations with diabetes were not significant in the fully adjusted model in either the depressive features or bipolar features groups. Odds ratios were reduced by approximately a quarter for many of the outcome measures on the additional adjustment for BMI, smoking, alcohol consumption and psychotropic medication.

### Current use of any psychotropic medication

We carried out a subanalysis to assess the contribution of current psychotropic medication use to cardiometabolic risk in the control group, the depressive features group and the bipolar features group. In total, 109 557 individuals without features of mood disorder who were not taking psychotropic medication were identified as a control group (Table 4). There were 3 867 individuals who did not meet the criteria for depressive or bipolar features but who reported taking one or more psychotropic medications (Table 4). Although the indication for these medications was not known, individuals who did not meet the criteria for depressive or bipolar disorder but reported taking one or more psychotropics displayed higher prevalences of all cardiometabolic diseases compared with controls. Of particular note were elevated rates of diabetes (8.97%), angina (5.87%), hypertension (36.07%) and stroke (3.98%) (Table 4).

As illustrated in Table 4, compared with controls not on psychotropic medication, individuals with depressive features plus no psychotropic medication had similar rates of diabetes, myocardial infarction, angina, hypertension and stroke. Participants with depressive features taking psychotropic medication had higher rates of all cardiometabolic diseases compared with controls not on psychotropic medication. Individuals with bipolar features not taking psychotropic medication had higher rates of cardiometabolic disease relative to controls not on psychotropic medication. As expected, cardiometabolic diseases were also more prevalent for individuals with bipolar features who reported taking psychotropic medication.

### Fully adjusted medication analyses

To assess the relative contribution of current psychotropic medication use in cardiometabolic disease across the mood spectrum we carried out a multivariate logistic regression adjusting for age, gender, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI (Fig. 1(a)–(f)). In general, odds ratios for most cardiometabolic diseases remained significantly elevated in each of the mood and medication groups relative to controls (Fig. 1(a)–(f)). Exceptions were for diabetes in the depressive features group not taking psychotropic medication, the bipolar features group not taking psychotropic medication, and the bipolar group currently taking psychotropic medication. Increases in odds ratios in the bipolar features group not on psychotropic medication group were

**Table 3** Logistic regression analysis of cardiometabolic disease associated with mood disorder<sup>a</sup>

	Partially adjusted <sup>b</sup>		Fully adjusted <sup>c</sup>	
	OR (95% CI)	P	OR (95% CI)	P
Cardiovascular disease any				
Control	1 (Reference)		1 (Reference)	
Depression	1.29 (1.25–1.33)	<0.001	1.15 (1.12–1.19)	<0.001
Bipolar	1.50 (1.34–1.68)	<0.001	1.28 (1.14–1.43)	<0.001
Diabetes				
Control	1 (Reference)		1 (Reference)	
Depression	1.29 (1.22–1.37)	<0.001	1.07 (1.03–1.13)	0.038
Bipolar	1.37 (1.15–1.67)	0.002	1.01 (0.81–1.24)	0.960
Hypertension				
Control	1 (Reference)		1 (Reference)	
Depression	1.27 (1.23–1.31)	<0.001	1.15 (1.13–1.18)	<0.001
Bipolar	1.44 (1.29–1.61)	<0.001	1.26 (1.12–1.42)	<0.001
Myocardial infarction				
Control	1 (Reference)		1 (Reference)	
Depression	1.38 (1.26–1.51)	<0.001	1.18 (1.08–1.30)	<0.001
Bipolar	1.90 (1.44–2.51)	<0.001	1.45 (1.09–1.92)	0.011
Angina				
Control	1 (Reference)		1 (Reference)	
Depression	1.49 (1.39–1.61)	<0.001	1.23 (1.14–1.33)	<0.001
Bipolar	1.69 (1.30–2.19)	<0.001	1.21 (0.93–1.58)	0.154
Stroke				
Control	1 (Reference)		1 (Reference)	
Depression	1.61 (1.46–1.78)	<0.001	1.26 (1.13–1.40)	<0.001
Bipolar	1.80 (1.27–2.54)	0.001	1.17 (0.82–1.67)	0.373

a. See online Table DS1 for a more detailed version of this table that includes data for men and women separately.  
b. Partially adjusted for age, gender, deprivation and ethnicity.  
c. Fully adjusted for age, gender, deprivation, ethnicity, body mass index, smoking status, alcohol consumption and psychotropic medication.

also not significantly elevated for angina (OR = 1.58, 95% CI 1.22–2.06) and stroke (OR = 1.70, 95% CI 1.20–2.41).

Furthermore, odds ratios for angina and stroke were not significantly elevated for both the bipolar features groups (those currently not taking psychotropic medication, as well as those taking psychotropic medication) (Fig. 1(d) and (f)). In general, however, the odds of reporting a history of an adverse cardiometabolic outcome were associated with both psychotropic medication use and with mood disorder (Fig. 1(a)–(f)) and the size of these associations increased with mood disorder severity (from depression to bipolar).

## Discussion


We found that in a very large population sample of adults with lifetime features of depression and bipolar disorder there was an increased risk of comorbid cardiovascular disorders, even after adjusting for a wide range of confounding factors. In general, these associations were more pronounced for individuals with features of bipolar disorder than features of depression. Perhaps unsurprisingly, we also identified an association between current

use of psychotropic medication and risk of cardiometabolic disease in individuals with a history of depressive and bipolar features. It is, however, notable that this association also occurred in individuals with no definite history of mood disorder who were currently taking psychotropic medication.

Both the bipolar features and depressive features groups had significantly higher odds ratios for 'any cardiovascular disease' relative to controls, within partially and fully adjusted models. Given the broad range of common confounding variables that were adjusted for, this suggests an independent association between mood disorder and cardiometabolic diseases. Within the partially adjusted (for age, gender, deprivation, ethnicity) versus fully adjusted models (additionally adjusted for BMI, smoking status, alcohol consumption and psychotropic medication), odds ratios for 'any cardiovascular disease' fell from 1.29 (partial) to 1.15 (full) within the depressive features group and from 1.50 (partial) to 1.28 (full) in the bipolar features group. Although depression has been considered a risk factor for cardiovascular disease for some time,<sup>18</sup> there has been debate about the relative contribution of lifestyle factors for this group of patients. We have been able to control for some of these lifestyle factors.

**Table 4** Cardiometabolic disease in mood and medication groups

Mood group	Total, n	n (%)				
		Diabetes	Myocardial infarction	Angina	Hypertension	Stroke
Controls not on psychotropic medication	109 577	5640 (5.15)	2262 (2.06)	2921 (2.67)	28 287 (25.81)	1316 (1.20)
Controls on psychotropic medication	3867	347 (8.97)	136 (3.52)	227 (5.87)	1395 (36.07)	154 (3.98)
Depressive features not on psychotropic medication	24 603	1199 (4.87)	508 (2.06)	690 (2.80)	6609 (26.86)	370 (1.50)
Depressive features on psychotropic medication	6387	531 (8.31)	168 (2.63)	321 (5.03)	2065 (32.33)	192 (3.01)
Bipolar features not on psychotropic medication	1057	108 (10.22)	55 (5.20)	63 (5.96)	484 (45.79)	34 (3.22)
Bipolar features on psychotropic medication	500	48 (9.60)	25 (5.00)	24 (4.80)	165 (33.00)	16 (3.20)



**Fig. 1** Logistic regression analysis of (a) any cardiovascular disease, (b) diabetes, (c) myocardial infarction, (d) angina, (e) hypertension and (f) stroke associated with mood disorder and medication status.

Results adjusted for age, gender, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and body mass index.

**Strengths and limitations**

The strengths of this study include the general population design, the breadth of coverage of confounding factors and the very large sample size. However, several limitations are acknowledged. Cardiometabolic disorders previously diagnosed by a physician were self-reported by the participants. Similarly, mood disorder features were self-reported, rather than assessed using a formal diagnostic interview, although a structured approach was used (Appendix). Psychiatric diagnoses based on formal interviews were not practical within UK Biobank, so we took a pragmatic approach to mood disorder groupings. It is possible that our criteria for mood disorder are less stringent than formal diagnostic criteria. It should be noted, however, that we are reporting features of mood disorders at a population level, rather than formal

clinical diagnoses, and we were unable to validate diagnoses because of the lack of availability of definitive diagnostic information. Similarly, because of a lack of definitive cardio-metabolic diagnostic information we were unable to validate outcome measures. This lack of validation for both cardio-metabolic and psychiatric diagnoses has implications in terms of the likely sensitivity and specificity of our groupings, which are based on self-report. Linkage to routine hospital and general practice health records will be available in the future and will allow some validation of these groups.

There is, however, evidence for the validity of these groupings using internal variables,<sup>19</sup> for example, the gender distributions of approximately 1:1 for bipolar disorder and approximately 2:1 (women:men) for depression are consistent with a large body of

epidemiological research on lifetime rates of mood disorder in men and women.<sup>20,21</sup> Furthermore, the lifetime prevalence rates for bipolar disorder (1.1%) and recurrent major depressive disorder (21.2%) are consistent with other population-based lifetime estimates.<sup>15</sup>

Although we are reasonably confident that members of the control groups did not have significant features of depression or bipolar disorder, it should be noted that a proportion may have fulfilled criteria for other mental illnesses, such as anxiety disorder or, less likely, schizophrenia, both of which have been associated with poor cardiometabolic health.<sup>19,22,23</sup> There are also limitations with our broad definition of current psychotropic medication use that groups together different classes of medication. In a subanalysis of individuals on psychotropic monotherapy, we found that selective serotonin reuptake inhibitors (SSRIs), other antidepressants and sedatives/hypnotics were all associated with greater risk of myocardial infarction relative to psychotropic-free controls (SSRIs OR = 1.82, 95% CI 1.51–2.21; other antidepressants OR = 1.50, 95% CI 1.20–1.87; and sedatives/hypnotics OR = 2.53, 95% CI 1.76–3.66). It is therefore possible that adverse cardiovascular outcomes in depressive disorders are not limited to the use of antipsychotics but may also be a consequence of other classes of psychotropic medications.

A relatively low proportion of the mood disorder features groups reported taking psychotropic medication (bipolar features 32.1%, depressive features 20.6% and controls 3.4%) but, as noted above, the focus in this study was not clinically diagnosed mood disordered groups but rather lifetime features of mood disorder at a population level. Poor adherence with medication may be an issue. According to some estimates, up to 50% of patients prescribed psychotropic medication do not take their medication regularly.<sup>24–26</sup> Although adherence for physical health medications may be slightly better than this,<sup>27</sup> it is likely that the factors that cause poor adherence with psychotropic medication may also lead to poor adherence with cardiovascular medications in individuals with mood disorders. This might explain the proportionately worse cardiovascular outcomes in a less adherent mood disordered group compared with a more adherent non-mood disordered group. As a result of the level of information on medication status that was collected at baseline, we were unable to assess the impact of duration of exposure to psychotropic medication on adverse cardiometabolic outcomes.

We included a range of possible confounding variables in the regression models but were unable to control for physical activity. The available data on physical activity were not collected in terms of standardised measures. Unfortunately, it was not possible to create a standardised measure, such as the metabolic equivalent of task (MET). Similarly, we were unable to adjust for the potential confounding effects of diet. When considering appropriate variables to include as confounding variables, it is important to note that there is uncertainty as to the extent that these variables might represent confounders or mediators. For example, obesity may represent an important component of the pathophysiology for depression, bipolar disorder and coronary heart disease. A prospective cohort study is required to address these concerns and is planned as part of future work in this cohort.

Our analyses did not assess the additive effects of socio-demographic and lifestyle factors. Rather, given the large number of confounding factors involved, we took a broad approach, focusing on cardiovascular outcomes after partial and full adjustment for confounders.

Severity of mood disorder may have contributed to the associations we observed. We therefore conducted an additional analysis of the impact of illness severity on cardiovascular disease outcomes. The depressive features group were divided into those who had a history of a probable single episode of major

depression, versus those with a history of probable moderate recurrent depression and those with probable severe recurrent depression (Appendix). The bipolar group was also split into those with features of probable bipolar type I illness and those with features of probable bipolar type II illness (Appendix). In general, individuals in the more severe mood disorder groups had higher risk of adverse cardiovascular outcomes. For the bipolar type I group the odds ratio of ‘any cardiovascular illness’ was 1.39 (95% CI 1.23–1.58), for the recurrent severe depression group the OR was 1.33 (95% CI 1.18–1.50) and for the bipolar type II group the OR was 1.21 (95% CI 1.09–1.32).

### Findings in the context of previous work

Many studies have identified an association between major depression and cardiovascular disease but relatively few studies have examined this with respect to bipolar disorder.<sup>28</sup> Although some reports in the literature support the association between bipolar disorder and cardiovascular disease,<sup>4,29–31</sup> these studies have not been able to adjust for the same range of confounding factors as our study.

Relative to controls, women with features of bipolar disorder had a greater risk of ‘any cardiovascular disease’ than men with bipolar features (OR 1.36 v. 1.19). This finding may be particularly noteworthy given that men are known to have increased rates of cardiovascular disease within the general population. In their 2013 population study, Crump and colleagues<sup>30</sup> reported increased all-cause mortality for women with bipolar disorder compared with men with bipolar disorder (adjusted hazard ratio of 2.13 compared with 1.74). Furthermore, the same study reported higher hazard ratios of death from ischaemic heart disease for women with bipolar disorder compared with men with bipolar disorder (2.14 compared with 1.73). Our findings add to the evidence that women with bipolar disorder may be disproportionately affected by cardiovascular disease.<sup>11</sup>

In our fully adjusted model for individuals with depressive or bipolar features, men (but not women) had an increased risk of myocardial infarction, and women (but not men) were at higher risk of stroke (Table DS1). There are several possible explanations for this, including studies that have found that men are more likely to receive a diagnosis of myocardial infarction than women<sup>32</sup> and that stroke is more commonly diagnosed in middle-aged women than in men.<sup>33</sup> We also found that, compared with both controls and women, men with depressive features had a higher risk of ‘any cardiovascular disease’ and hypertension, supporting previous findings in this area.<sup>11</sup> Furthermore, we found that in the combined male and female results, depressive features were associated with an increased risk of ‘any cardiovascular disease’. Although odds ratios were not as large as previous studies<sup>12</sup> this may underscore the importance of adjusting for a wide variety of confounding factors where possible.

### Possible mechanisms

There are several possible underlying mechanisms for the associations we have observed, including shared behavioural factors, inequalities in treatment, shared genetic vulnerabilities and shared pathophysiology. Individuals with mood disorder may have difficulties in accessing preventative medical interventions, as well as higher rates of risky lifestyle factors.<sup>34</sup> Such factors include smoking, physical inactivity and reduced adherence with cardiovascular medications.<sup>35,36</sup> In keeping with other work, smoking was more common in the bipolar features group than the depressive features and control groups.<sup>37</sup> Given the negative impact of smoking on cardiovascular health,<sup>38</sup> this is clearly relevant to our findings of increased cardiovascular risk in both the bipolar

and depressive features groups. Our results also show a significant attenuation in odds ratios when moving from partially adjusted to fully adjusted analyses, underlining the impact of smoking, alcohol, medication and BMI on cardiovascular risk in individuals with depressive and bipolar features.

Although our study adds to knowledge on the possible contribution of lifestyle and demographic factors to the association between cardiometabolic disease and mood disorder, it cannot contribute substantially to understanding pathophysiological mechanisms. Several biological systems may contribute to the comorbidity between mood disorder and cardiometabolic disease, including (but not limited to) abnormalities of the hypothalamic–pituitary–adrenal (HPA) axis,<sup>39–42</sup> oxidative stress processes,<sup>43</sup> shared genetic vulnerability,<sup>44–47</sup> abnormal inflammatory responses,<sup>48,49</sup> endothelial dysfunction<sup>50,51</sup> and haemodynamic reactivity.<sup>52</sup>

We did, however, find that the use of psychotropic medication was associated with an increased risk of cardiovascular disease in all groups, even those without features of mood disorder. The metabolic effects of psychotropic medications are known to increase cardiometabolic risk by various mechanisms, including weight gain<sup>53</sup> and impaired glucose tolerance.<sup>54</sup> Given that our analyses were conducted on the basis of current use of any psychotropic medication, it is perhaps noteworthy that adverse cardiometabolic effects may not be limited to antipsychotics. There are reports in the literature of other psychotropic medications used in the treatment of mood disorder, such as antidepressants, lithium and valproic acid, having adverse metabolic effects.<sup>55–57</sup>

### Future work

There remain several unanswered questions and opportunities for further research. There is a need for longitudinal and mechanistic studies in this area to better understand causal pathways.<sup>58</sup> To date, very few studies have tested specific genetic associations between lifestyle-related risk factors for cardiometabolic disease across the broad clinical spectrum of mood disorders. In addition, further mechanistic studies examining epigenetic factors, as well as oxidative stress, endothelial dysfunction and HPA axis abnormalities will be important to better understand comorbidity between mood disorder and cardiometabolic disease.

**Daniel J. Martin**, MRCPsych, Institute of Health and Wellbeing, Mental Health, University of Glasgow, Gartnavel Royal Hospital, Glasgow, UK; **Zia Ul-Haq**, PhD, Institute of Health and Wellbeing, Public Health, University of Glasgow, Glasgow, UK and Institute of Public Health & Social Sciences, Khyber Medical University, Peshawar, Pakistan; **Barbara I. Nicholl**, PhD, Institute of Health and Wellbeing, General Practice and Primary Care, University of Glasgow, Glasgow, UK; **Breda Cullen**, DClinPsy, **Jonathan Evans**, PhD, Institute of Health and Wellbeing, Mental Health, University of Glasgow, Gartnavel Royal Hospital, Glasgow, UK; **Jason M. R. Gill**, PhD, Institute of Health and Wellbeing, Public Health, University of Glasgow, Glasgow, UK; **Beverly Roberts**, PhD, Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, UK; **John Gallacher**, PhD, National Centre for Mental Health, Institute of Neurosciences and Mental Health, Cardiff University, Cardiff, UK; **Daniel Mackay**, PhD, Institute of Health and Wellbeing, Public Health, University of Glasgow, Glasgow, UK; **Andrew McIntosh**, MD, FRCPsych, Division of Psychiatry, University of Edinburgh, Edinburgh, UK; **Matthew Hotopf**, MD, FRCPsych, Institute of Psychiatry, Kings College, London, London, UK; **Nick Craddock**, PhD, FRCPsych, National Centre for Mental Health, Institute of Neurosciences and Mental Health, Cardiff University, Cardiff, UK; **Ian J. Deary**, PhD, Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, UK; **Jill P. Pell**, MD, Institute of Health and Wellbeing, Public Health, University of Glasgow, Glasgow, UK; **Daniel J. Smith**, MD, FRCPsych, Institute of Health and Wellbeing, Mental Health, University of Glasgow, Gartnavel Royal Hospital, Glasgow, UK.

**Correspondence:** Daniel J. Smith, Institute of Health and Wellbeing, Mental Health, University of Glasgow, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow G12 0XH. UK. Email daniel.smith@glasgow.ac.uk

First received 18 Sep 2014, final revision 2 Jun 2015, accepted 2 Jun 2015

### Funding

This research has been conducted using the UK Biobank resource. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department

of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Appendix

### Criteria for lifetime features of bipolar disorder and depression

#### Bipolar disorder features

- Features of bipolar disorder, type I: ever 'manic or hyper' for at least 2 days OR ever 'irritable/argumentative' for 2 days; plus at least 3 features from 'more active', 'more talkative', 'needed less sleep' and 'more creative/more ideas'; plus duration of a week or more; plus 'needed treatment or caused problems at work'.
- Features of bipolar disorder, type II: ever 'manic or hyper' for at least 2 days OR ever 'irritable/argumentative' for 2 days; plus at least 3 features from 'more active', 'more talkative', 'needed less sleep' and 'more creative/more ideas'; plus duration of a week or more.

#### Major depression features

- Features of single-episode major depression: ever depressed/down for a whole week; plus at least 2 weeks duration; plus only one episode; plus ever seen a general practitioner (GP) or a psychiatrist for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least 2 weeks duration; plus only one episode; plus ever seen a GP or a psychiatrist for 'nerves, anxiety, depression'.
- Features of recurrent major depression (moderate): ever depressed/down for a whole week; plus at least 2 weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least 2 weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for 'nerves, anxiety, depression'.
- Features of recurrent major depression (severe): ever depressed/down for a whole week; plus at least 2 weeks duration; plus at least 2 episodes; plus ever seen a psychiatrist for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least 2 weeks duration; plus at least two episodes; plus ever seen a psychiatrist for 'nerves, anxiety, depression'.

## References

- Merikangas KR1, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. *Arch Gen Psychiatry* 2007; **64**: 543–52.
- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; **62**: 617–27.
- Martin DJ, Smith DJ. Is there a clinical prodrome of bipolar disorder? A review of the evidence. *Expert Rev Neurother* 2013; **13**: 89–98.
- Ösby U, Brandt L, Correia N, Ekbo M, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. *Arch Gen Psychiatry* 2001; **58**: 844–50.
- Kemp DE, Sylvia LG, Calabrese JR, Nierenberg AA, Thase ME, Reilly-Harrington NA, et al. General medical burden in bipolar disorder: findings from the LITMUS comparative effectiveness trial. *Acta Psychiatr Scand* 2014; **129**: 24–34.
- McIntyre R, Konarski J, Soczynska J, Wilkins K, Panjwani G, Bouffard B, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. *Psychiatr Serv* 2006; **57**: 1140–4.
- Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007; **370**: 851–8.
- Stommel M, Given BA, Given CW. Depression and functional status as predictors of death among cancer patients. *Cancer* 2002; **94**: 2719–27.
- Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. *Am J Psychiatry* 1998; **155**: 4–11.



- 10 Ormel J, Von Korff M, Burger H, Scott K, Demyttenaere K, Huang YQ, et al. Mental disorders among persons with heart disease - results from World Mental Health surveys. *Gen Hosp Psychiatry* 2007; **29**: 325–34.
- 11 Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. *J Psychosom Res* 2011; **70**: 145–54.
- 12 Herbst S, Pietrzak RH, Wagner J, White WB, Petry NM. Lifetime major depression is associated with coronary heart disease in older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychosom Med* 2007; **69**: 729–34.
- 13 Britvic D, Maric NP, Doknic M, Pekic S, Andric S, Jasovic-Gasic M, et al. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. *Psychiatr Danub* 2013; **25**: 410–5.
- 14 Collins R. What makes UK Biobank special? *Lancet* 2012; **379**: 1173–4.
- 15 Smith DJ, Nicholl B, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK Biobank: cross-sectional study of 172,751 participants. *PLoS One* 2013; **8**: e75362.
- 16 Langan J, Mercer SW, Smith DJ. Multimorbidity and mental health: can psychiatry rise to the challenge? *Br J Psychiatry* 2013; **202**: 391–3.
- 17 Ul-Haq Z, Mackay DF, Martin D, Smith DJ, Gill JM, Nicholl BI, et al. Heaviness, health and happiness: a cross-sectional study of 163 066 UK Biobank participants. *J Epidemiol Community Health* 2014; **68**: 340–8.
- 18 Elderon L, Whooley MA. Depression and cardiovascular disease. *Prog Cardiovasc Dis* 2013; **55**: 511–23.
- 19 Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. *PLoS One* 2013; **8**: e55176.
- 20 Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. *J Affect Disord* 1993; **29**: 85–96.
- 21 Hwu H-G, Joyce PR, Karam EG, Lee C-K, Lellouch J, Wickramaratne PJ, et al. Cross-national epidemiology of major depression and bipolar disorder. *JAMA* 1996; **276**: 293–9.
- 22 De Hert, M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry* 2011; **10**: 52–77.
- 23 Lahti M, Tiihonen J, Wildgust H, Beary M, Hodgson R, Kajantie E, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. *Psychol Med* 2012; **42**: 2275–85.
- 24 Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. *CNS Spectr* 2007; **12** (suppl 13): 1–27.
- 25 Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *J Clin Psychiatry* 2002; **63**: 892–909.
- 26 Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? *BMC Health Serv Res* 2012; **12**: 98.
- 27 Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. *Psychiatr Serv* 1998; **49**: 196–201.
- 28 Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. *Eur Heart J* 2014; **35**: 1365–72.
- 29 Ramsey CM, Leoutsakos JM, Mayer LS, Eaton WW, Lee HB. History of manic and hypomanic episodes and risk of incident cardiovascular disease: 11.5 year follow-up from the Baltimore Epidemiologic Catchment Area Study. *J Affect Disord* 2010; **125**: 35–41.
- 30 Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. *JAMA Psychiatry* 2013; **70**: 931–9.
- 31 Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. *Ann Clin Psychiatry* 2011; **23**: 40–7.
- 32 Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ* 2015; **350**: g7873.
- 33 Towfighi A, Saver JL, Engelhardt R, Ovbiagele B. A midlife stroke surge among women in the United States. *Neurology* 2007; **69**: 1898–904.
- 34 Carney RM, Freedland KE. Depression in patients with coronary heart disease. *Am J Med* 2008; **121** (suppl 2): S20–7.
- 35 Freedland KE, Carney RM, Skala JA. Depression and smoking in coronary heart disease. *Psychosom Med* 2005; **67** (suppl 1): S42–6.
- 36 Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. *JAMA* 2008; **300**: 2379–88.
- 37 Heffner JL, Strawn JR, DelBello MP, Strakowski SM, Anthenelli RM. The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. *Bipolar Disord* 2011; **13**: 439–53.
- 38 Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. *Circulation* 2005; **112**: 489–97.
- 39 Rosmond R, Björntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. *J Intern Med* 2000; **247**: 188–97.
- 40 Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. *Br J Psychiatry* 2004; **184**: 496–502.
- 41 Holsboer F, Lauer CJ, Schreiber W, Krieg JC. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. *Neuroendocrinology* 1995; **62**: 340–7.
- 42 Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. *Psychol Med* 2002; **32**: 1021–8.
- 43 Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. *Redox Rep* 2003; **8**: 365–70.
- 44 Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. *Arch Gen Psychiatry* 2009; **66**: 857–63.
- 45 Scherrer JF, Xian H, Bucholz KK, Eisen SA, Lyons MJ, Goldberg J, et al. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. *Psychosom Med* 2003; **65**: 548–57.
- 46 McCaffery JM, Frasure-Smith N, Dube MP, Theroux P, Rouleau GA, Duan Q, et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. *Psychosom Med* 2006; **68**: 187–200.
- 47 Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. *Genomics* 2008; **92**: 265–72.
- 48 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**: 1685–95.
- 49 Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction. *Biol Psychiatry* 2003; **54**: 248–61.
- 50 Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. *Biol Psychiatry* 2006; **60**: 889–91.
- 51 Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest* 1996; **97**: 2601–10.
- 52 Strike PC, Steptoe A. Psychosocial factors in the development of coronary artery disease. *Prog Cardiovasc Dis* 2004; **46**: 337–47.
- 53 Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. *Am J Prev Med* 2009; **36**: 341–50.
- 54 Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. *Am J Psychiatry* 2002; **159**: 561–6.
- 55 Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M, et al. Lithium and body weight gain. *Pharmacopsychiatry* 1995; **28**: 35–44.
- 56 McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. *Bipolar Disord* 2003; **5**: 28–35.
- 57 Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. *J Clin Psychiatry* 2000; **61**: 863–7.
- 58 Faith MS, Matz PE, Jorge MA. Obesity–depression associations in the population. *J Psychosom Res* 2002; **53**: 935–42.

